Dyne's Third-Quarter Loss Widens as Launch Spending Rises

The Tip Desk · November 11, 2026 · 3 min read

The neuromuscular biotech posted a $193.6 million net loss, or $1.06 a share, as it prepared for a potential first-quarter 2027 launch of z-rostudirsen.

Dyne Therapeutics (DYN), a clinical-stage company developing treatments for genetically driven neuromuscular diseases, reported a net loss of $193.6 million, or $1.06 a share, for the three months ended September 30, 2026, compared with a net loss of $108.0 million, or $0.76 a share, a year earlier. Weighted-average shares outstanding rose to 181.8 million from 141.8 million.

The widening loss tracked a step-up in spending as the company moved closer to commercialization. Research and development expenses were $161.7 million, up from $97.2 million a year earlier. The company said the increase was primarily due to higher manufacturing activity for z-rostudirsen and higher clinical-trial costs for the ongoing Phase 3 FORZETTO and HARMONIA studies of z-rostudirsen and z-basivarsen. General and administrative expenses were $35.3 million, versus $16.7 million a year earlier, which the company attributed primarily to preparation for a potential launch of z-rostudirsen, including an increase in headcount. Total operating expenses were $197.1 million. Other income, net, was $3.5 million.

Cash, cash equivalents and marketable securities were $1.134 billion as of September 30, 2026. Dyne said that balance would be sufficient to fund operations into the second quarter of 2028. Stockholders’ equity was $930.9 million.

President and chief executive officer John Cox said the company is investing across multiple programs to unlock the full value of its FORCE platform, including preparations for a potential U.S. launch of z-rostudirsen for exon 51 Duchenne muscular dystrophy, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in myotonic dystrophy type 1, both expected in the first quarter of 2027.

The biologics license application for z-rostudirsen in exon 51 DMD remained under priority review by the FDA, with a PDUFA target action date of January 21, 2027. Dyne continues to expect a potential U.S. launch of z-rostudirsen in the first quarter of 2027, assuming approval is received on the anticipated timeline. The ongoing confirmatory Phase 3 FORZETTO trial is intended to support conversion of Accelerated Approval, if granted, to traditional approval in the U.S. and to support ex-U.S. marketing applications.

In DM1, Dyne presented additional one-year efficacy data from the multiple ascending dose portion of the Phase 1/2 ACHIEVE trial at the World Muscle Society congress and the American Association of Neuromuscular & Electrodiagnostic Medicine meeting. Data from a pooled dose group showed functional improvement versus baseline, versus placebo and versus a matched natural-history cohort across multiple measures at 12 months, the company said. Topline data from the ACHIEVE registrational expansion cohort are planned for the first quarter of 2027 to support a potential BLA submission for U.S. Accelerated Approval in the third quarter of 2027. Dyne expects a potential U.S. launch of z-basivarsen in the first half of 2028, assuming the FDA grants Priority Review and approval is received on the anticipated timeline. The ongoing Phase 3 HARMONIA trial is intended to support conversion of Accelerated Approval, if granted, to traditional approval in the U.S. and to support ex-U.S. marketing applications.

Beyond the two lead programs, Dyne is advancing four development candidates — DYNE-244, DYNE-245, DYNE-253 and DYNE-255 — for DMD amenable to skipping of exons 44, 45, 53 and 55, respectively. Preclinical data supporting those programs were presented at the 27th Annual Neuromuscular Study Group Scientific Meeting. Cox said the company is progressing four preclinical DMD programs that have the potential to expand its reach to over one third of individuals living with Duchenne.

The company said it is also advancing preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.